Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | The movement of BCMA-directed therapies to earlier lines in myeloma treatment

Amrita Krishnan • 2 Jun 2024
ASCO 2024
Multiple Myeloma Antibodies CAR-T
DREAMM-7 DREAMM-8

Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses moving BCMA-directed therapies to earlier lines in myeloma treatment. She highlights the need to identify ideal candidates for CAR-T at first relapse and notes that positive results from the DREAMM-7 and DREAMM-8 trials have added antibody-drug conjugates (ADCs) to the treatment options. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amrita Krishnan

0:49
Management of patients with penta-class refractory myeloma
Amrita Krishnan • 11 Dec 2023
1:01
Considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Amrita Krishnan • 11 Dec 2023
0:50
Dose modifications of talquetamab to manage AEs in patients with multiple myeloma
Amrita Krishnan • 11 Dec 2023
1:15
How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma
Amrita Krishnan • 29 Sep 2022

Related Videos

1:27
The real world utilization of MRD in myeloma across Europe
Bruno Paiva • 16 Jun 2024
2:41
Real-world dose de-escalation of teclistamab in patients with R/R myeloma
Saad Usmani • 17 Jun 2024
0:58
Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials
Meletios Dimopoulos • 13 Jun 2024
0:43
The use of oral ixazomib maintenance following autoSCT in patients with NDMM
Meletios Dimopoulos • 13 Jun 2024
The content of VJHemOnc is intended for healthcare professionals